---
document_datetime: 2025-12-29 12:05:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-medac.html
document_name: leflunomide-medac.html
version: success
processing_time: 0.1136459
conversion_datetime: 2025-12-30 03:38:23.377709
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Leflunomide medac

[RSS](/en/individual-human-medicine.xml/65909)

##### Authorised

This medicine is authorised for use in the European Union

leflunomide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Leflunomide medac. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Leflunomide medac.

Expand section

Collapse section

## What is Leflunomide medac?

Leflunomide medac is a medicine that contains the active substance leflunomide. It is available as tablets (10, 15 and 20 mg).

Leflunomide medac is a 'generic medicine'. This means that Leflunomide medac is similar to a 'reference medicine' already authorised in the European Union (EU) called Arava.

## What is Leflunomide medac used for?

Leflunomide medac is used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints).

The medicine can only be obtained with a prescription.

## How is Leflunomide medac used?

Leflunomide medac treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis. The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Leflunomide medac, and regularly during treatment.

Leflunomide medac treatment usually starts with a 'loading dose' of 100 mg once a day for three days, followed by a maintenance dose. The recommended maintenance dose is 10 to 20 mg once a day in patients with rheumatoid arthritis, and 20 mg once a day in patients with psoriatic arthritis. The medicine usually starts to have an effect after four to six weeks. Its effect may improve further for up to six months.

## How does Leflunomide medac work?

The active substance in Leflunomide medac, leflunomide, is an immunosuppressant. It reduces inflammation by reducing the production of immune cells called 'lymphocytes', which are responsible for inflammation. Leflunomide does this by blocking an enzyme called 'dihydroorotate dehydrogenase', which is necessary for the lymphocytes to multiply. With fewer lymphocytes, there is less inflammation, helping to control the symptoms of arthritis.

## How has Leflunomide medac been studied?

Because Leflunomide medac is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Arava. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Leflunomide medac?

Because Leflunomide medac is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.

## Why has Leflunomide medac been approved?

The CHMP concluded that, in accordance with EU requirements, Leflunomide medac has been shown to have comparable quality and to be bioequivalent to Arava. Therefore, the CHMP's view was that, as for Arava, the benefit outweighs the identified risk. The Committee recommended that Leflunomide medac be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Leflunomide medac ?

A risk management plan has been developed to ensure that Leflunomide medac is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Leflunomide medac, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Leflunomide medac

The European Commission granted a marketing authorisation valid throughout the European Union for Leflunomide medac on 27 July 2010.

Leflunomide medac : EPAR - Summary for the public

English (EN) (79.19 KB - PDF)

**First published:** 05/08/2010

**Last updated:** 12/08/2014

[View](/en/documents/overview/leflunomide-medac-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-345)

български (BG) (131.97 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/bg/documents/overview/leflunomide-medac-epar-summary-public_bg.pdf)

español (ES) (103.64 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/es/documents/overview/leflunomide-medac-epar-summary-public_es.pdf)

čeština (CS) (104.71 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/cs/documents/overview/leflunomide-medac-epar-summary-public_cs.pdf)

dansk (DA) (80.44 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/da/documents/overview/leflunomide-medac-epar-summary-public_da.pdf)

Deutsch (DE) (83.14 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/de/documents/overview/leflunomide-medac-epar-summary-public_de.pdf)

eesti keel (ET) (81.28 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/et/documents/overview/leflunomide-medac-epar-summary-public_et.pdf)

ελληνικά (EL) (133.55 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/el/documents/overview/leflunomide-medac-epar-summary-public_el.pdf)

français (FR) (82.97 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/fr/documents/overview/leflunomide-medac-epar-summary-public_fr.pdf)

hrvatski (HR) (100.55 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/hr/documents/overview/leflunomide-medac-epar-summary-public_hr.pdf)

italiano (IT) (81.6 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/it/documents/overview/leflunomide-medac-epar-summary-public_it.pdf)

latviešu valoda (LV) (101.19 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/lv/documents/overview/leflunomide-medac-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (103.57 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/lt/documents/overview/leflunomide-medac-epar-summary-public_lt.pdf)

magyar (HU) (102.44 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/hu/documents/overview/leflunomide-medac-epar-summary-public_hu.pdf)

Malti (MT) (106.92 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/mt/documents/overview/leflunomide-medac-epar-summary-public_mt.pdf)

Nederlands (NL) (82.07 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/nl/documents/overview/leflunomide-medac-epar-summary-public_nl.pdf)

polski (PL) (106.66 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/pl/documents/overview/leflunomide-medac-epar-summary-public_pl.pdf)

português (PT) (82.08 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/pt/documents/overview/leflunomide-medac-epar-summary-public_pt.pdf)

română (RO) (126.31 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/ro/documents/overview/leflunomide-medac-epar-summary-public_ro.pdf)

slovenčina (SK) (105.24 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/sk/documents/overview/leflunomide-medac-epar-summary-public_sk.pdf)

slovenščina (SL) (98.18 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/sl/documents/overview/leflunomide-medac-epar-summary-public_sl.pdf)

Suomi (FI) (80.43 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/fi/documents/overview/leflunomide-medac-epar-summary-public_fi.pdf)

svenska (SV) (82.12 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

12/08/2014

[View](/sv/documents/overview/leflunomide-medac-epar-summary-public_sv.pdf)

## Product information

Leflunomide medac : EPAR - Product Information

English (EN) (401.37 KB - PDF)

**First published:** 05/08/2010

**Last updated:** 19/12/2025

[View](/en/documents/product-information/leflunomide-medac-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-420)

български (BG) (512.13 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/leflunomide-medac-epar-product-information_bg.pdf)

español (ES) (459.29 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/es/documents/product-information/leflunomide-medac-epar-product-information_es.pdf)

čeština (CS) (583.02 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/leflunomide-medac-epar-product-information_cs.pdf)

dansk (DA) (449.98 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/da/documents/product-information/leflunomide-medac-epar-product-information_da.pdf)

Deutsch (DE) (373.13 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/de/documents/product-information/leflunomide-medac-epar-product-information_de.pdf)

eesti keel (ET) (444.6 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/et/documents/product-information/leflunomide-medac-epar-product-information_et.pdf)

ελληνικά (EL) (532.77 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/el/documents/product-information/leflunomide-medac-epar-product-information_el.pdf)

français (FR) (392.28 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/leflunomide-medac-epar-product-information_fr.pdf)

hrvatski (HR) (515.69 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/leflunomide-medac-epar-product-information_hr.pdf)

íslenska (IS) (350.17 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/is/documents/product-information/leflunomide-medac-epar-product-information_is.pdf)

italiano (IT) (423.25 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/it/documents/product-information/leflunomide-medac-epar-product-information_it.pdf)

latviešu valoda (LV) (534.35 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/leflunomide-medac-epar-product-information_lv.pdf)

lietuvių kalba (LT) (520.36 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/leflunomide-medac-epar-product-information_lt.pdf)

magyar (HU) (533.85 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/leflunomide-medac-epar-product-information_hu.pdf)

Malti (MT) (583.4 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/leflunomide-medac-epar-product-information_mt.pdf)

Nederlands (NL) (355.83 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/leflunomide-medac-epar-product-information_nl.pdf)

norsk (NO) (399.89 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/no/documents/product-information/leflunomide-medac-epar-product-information_no.pdf)

polski (PL) (545.89 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/leflunomide-medac-epar-product-information_pl.pdf)

português (PT) (425.85 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/leflunomide-medac-epar-product-information_pt.pdf)

română (RO) (558.92 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/leflunomide-medac-epar-product-information_ro.pdf)

slovenčina (SK) (507.43 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/leflunomide-medac-epar-product-information_sk.pdf)

slovenščina (SL) (510.25 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/leflunomide-medac-epar-product-information_sl.pdf)

Suomi (FI) (444.92 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/leflunomide-medac-epar-product-information_fi.pdf)

svenska (SV) (404.42 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/leflunomide-medac-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000315571 19/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Leflunomide medac : EPAR - All Authorised presentations

English (EN) (25.06 KB - PDF)

**First published:** 05/08/2010

**Last updated:** 02/08/2017

[View](/en/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-692)

български (BG) (53.44 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/bg/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.81 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/es/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.78 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/cs/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27.72 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/da/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.32 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/de/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.17 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/et/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (50.03 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/el/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_el.pdf)

français (FR) (27.67 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/fr/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.56 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/hr/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (27.34 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/is/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.05 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/it/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.75 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/lv/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (44.48 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/lt/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (33.22 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/hu/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.62 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/mt/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (26.75 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/nl/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (28.68 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/no/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_no.pdf)

polski (PL) (35.5 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/pl/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.4 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/pt/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_pt.pdf)

română (RO) (44.33 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/ro/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (42.91 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/sk/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.02 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/sl/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (27.75 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/fi/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.74 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

02/08/2017

[View](/sv/documents/all-authorised-presentations/leflunomide-medac-epar-all-authorised-presentations_sv.pdf)

Leflunomide medac : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (19.14 KB - PDF)

**First published:** 05/08/2010

**Last updated:** 05/08/2010

[View](/en/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (21)](#file-language-dropdown-33)

български (BG) (105.97 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/bg/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (18.71 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/es/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (93.76 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/cs/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (19.81 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/da/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (23.57 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/de/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (23.22 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/et/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (89.13 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/el/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (23.43 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/fr/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

italiano (IT) (18.89 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/it/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (90.74 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/lv/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (88.7 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/lt/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (63.43 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/hu/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (92.84 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/mt/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (19.3 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/nl/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

polski (PL) (91.97 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/pl/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (23.41 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/pt/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (88.54 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/ro/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (90.25 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/sk/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (88.21 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/sl/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (18.58 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/fi/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (22.56 KB - PDF)

**First published:**

05/08/2010

**Last updated:**

05/08/2010

[View](/sv/documents/conditions-member-states/leflunomide-medac-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Leflunomide medac Active substance leflunomide International non-proprietary name (INN) or common name leflunomide Therapeutic area (MeSH) Arthritis, Rheumatoid Anatomical therapeutic chemical (ATC) code L04AK01

### Pharmacotherapeutic group

Selective immunosuppressants

### Therapeutic indication

Leflunomide is indicated for the treatment of adult patients with:

- active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).

Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.

Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

## Authorisation details

EMA product number EMEA/H/C/001227

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

medac Gesellschaft für klinische Spezialpräparate mbH

Theaterstrasse 6

Marketing authorisation issued 27/07/2010 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Leflunomide medac : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.21 KB - PDF)

**First published:** 04/07/2025

**Last updated:** 19/12/2025

[View](/en/documents/procedural-steps-after/leflunomide-medac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Leflunomide medac : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (141.02 KB - PDF)

**First published:** 26/09/2011

**Last updated:** 04/07/2025

[View](/en/documents/procedural-steps-after/leflunomide-medac-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Leflunomide medac-H-C-PSUSA-00001837-202309 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/352161/2024

English (EN) (91.27 KB - PDF)

**First published:** 30/07/2024

[View](/en/documents/scientific-conclusion/leflunomide-medac-h-c-psusa-00001837-202309-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Leflunomide medac-H-C-1227-X-0012-G : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/CHMP/478482/2013

English (EN) (243.72 KB - PDF)

**First published:** 08/10/2013

**Last updated:** 08/10/2013

[View](/en/documents/variation-report/leflunomide-medac-h-c-1227-x-0012-g-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Leflunomide medac : EPAR - Public assessment report

English (EN) (324.42 KB - PDF)

**First published:** 05/08/2010

**Last updated:** 05/08/2010

[View](/en/documents/assessment-report/leflunomide-medac-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Leflunomide medac

Adopted

Reference Number: EMA/CHMP/291554/2010

English (EN) (77.29 KB - PDF)

**First published:** 21/05/2010

**Last updated:** 21/05/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-leflunomide-medac_en.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)